What is claimed is:

1. Use of durvalumab or an antigen binding fragment thereof, and an etoposide and cisplatin or carboplatin-in the manufacture of a medicament for extending progression-free survival (PFS) in a patient with extensive-stage small cell lung cancer (ES-SCLC), wherein the medicament comprising

a) durvalumab or an antigen binding fragment thereof comprising:

a VH CDR1 having the amino acid sequence of SEQ ID NO: 3,

a VH CDR2 having the amino acid sequence of SEQ ID NO: 4,

a VH CDR3 having the amino acid sequence of SEQ ID NO: 5,

a VL CDR1 having the amino acid sequence of SEQ ID NO: 6,

a VL CDR2 having the amino acid sequence of SEQ ID NO: 7, and

a VL CDR3 having the amino acid sequence of SEQ ID NO: 8; and

b) EP, wherein the durvalumab or binding fragment thereof is to be administered as a fixed dose of 1500 mg, every three weeks (Q3W), as a treatment phase followed by a maintenance phase wherein the durvalumab or the antigen binding fragment thereof is to be administered as a fixed dose of 1500 mg, every four weeks (Q4W),

wherein PFS is increased by at least five months versus treatment with EP alone.

2. The use of claim 1, wherein the durvalumab or antigen binding fragment thereof comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

3. The use of claim 1, wherein the durvalumab is to be administered intravenously during the treatment phase.

4. The use of claim 1, wherein the use comprises 4 cycles of administration of durvalumab or the antigen binding fragment thereof during the treatment phase.

5. The use of claim 1, wherein EP is to be administered as a dose comprising 80-100 mg/m^2 etoposide and carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m^2, intravenously, per dose of durvalumab.

6. The use of claim 1, wherein the durvalumab or antibody fragment thereof is to be administered, intravenously during the maintenance phase.

7. The use of claim 1, wherein the use further comprises administration of a human anti-CTLA-4 antibody, intravenously, Q3W, wherein the human anti-CTLA-4 antibody is tremelimumab.

8. The use of claim 7, wherein tremelimumab is to be administered as a fixed dose of 75 mg or as a dose of 1 mg/kg.

9. The use according to any of the preceding claims, wherein the use further comprises administration of prophylactic cranial irradiation to the patient.

10. Use of durvalumab or an antigen binding fragment thereof, and an etoposide and cisplatin or carboplatin in the manufacture of a medicament for extending overall survival (OS) in a patient with extensive-stage small cell lung cancer (ES-SCLC), wherein the medicament comprising

a) durvalumab or an antigen binding fragment thereof comprising:

a VH CDR1 having the amino acid sequence of SEQ ID NO: 3,

a VH CDR2 having the amino acid sequence of SEQ ID NO: 4,

a VH CDR3 having the amino acid sequence of SEQ ID NO: 5,

a VL CDR1 having the amino acid sequence of SEQ ID NO: 6,

a VL CDR2 having the amino acid sequence of SEQ ID NO: 7, and

a VL CDR3 having the amino acid sequence of SEQ ID NO: 8; and

b) EP, wherein the durvalumab or binding fragment thereof is to be administered as a fixed dose of 1500 mg, intravenously, every three weeks (Q3W), as a treatment phase followed

by a maintenance phase wherein the durvalumab or the antigen binding fragment thereof is to be administered as a fixed dose of 1500 mg every four weeks (Q4W),

wherein OS is extended by at least three months versus treatment with EP alone.

11. The use of claim 10, wherein the durvalumab or antigen binding fragment thereof comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

12. The use of claim 10, wherein the durvalumab is to be administered, intravenously during the treatment phase.

13. The use of claim 10, wherein the use comprises 4 cycles of administration of durvalumab or the antigen binding fragment thereof during the treatment phase.

14. The use of claim 10, wherein EP is to be administered as a dose comprising 80-100 mg/m^2 etoposide and carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m^2, intravenously, per dose of durvalumab.

15. The use of claim 10, wherein the durvalumab or antibody fragment thereof is to be administered, intravenously during the maintenance phase.

16. The use of claim 10, wherein the use further comprises administration of a human anti-CTLA-4 antibody, intravenously, Q3W, wherein the human anti-CTLA-4 antibody is tremelimumab.

17. The use of claim 10, wherein tremelimumab is to be administered as a fixed dose of 75 mg or as a dose of 1 mg/kg.

18. The use according to any one of claims 10-17, wherein the use further comprises administration of prophylactic cranial irradiation to the patient.

19. Use of durvalumab or an antigen binding fragment thereof, and an etoposide and cisplatin or carboplatin in the manufacture of a medicament for extending overall response rate (ORR) in a patient with extensive-stage small cell lung cancer (ES-SCLC), wherein the medicament comprising

a) durvalumab or an antigen binding fragment thereof comprising:

a VH CDR1 having the amino acid sequence of SEQ ID NO: 3,

a VH CDR2 having the amino acid sequence of SEQ ID NO: 4,

a VH CDR3 having the amino acid sequence of SEQ ID NO: 5,

a VL CDR1 having the amino acid sequence of SEQ ID NO: 6,

a VL CDR2 having the amino acid sequence of SEQ ID NO: 7, and

a VL CDR3 having the amino acid sequence of SEQ ID NO: 8; and

b) EP, wherein the durvalumab or binding fragment thereof is to be administered as a fixed dose of 1500 mg, intravenously, every three weeks (Q3W) as a treatment phase followed by a maintenance phase wherein the durvalumab or the antigen binding fragment thereof is to be administered as a fixed dose of 1500 mg, intravenously every four weeks (Q4W),

wherein ORR is increased by at least 10% versus treatment with EP alone.

20. The use of claim 19, wherein the durvalumab comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

21. The use of claim 19, wherein the durvalumab is to be administered intravenously during the treatment phase.

22. The use of claim 19, wherein the use comprises 4 cycles of administration of durvalumab or the antigen binding fragment thereof during the treatment phase.

23. The use of claim 19, wherein EP is to be administered as a dose comprising 80-100 mg/m^2 etoposide and carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m^2, intravenously, per dose of durvalumab.

24. The use of claim 19, wherein the durvalumab or antibody fragment thereof is to be administered, intravenously during the maintenance phase.

25. The use of claim 19, wherein the use further comprises administration of a human anti-CTLA-4 antibody, intravenously, Q3W wherein the human anti-CTLA-4 antibody is tremelimumab.

26. The use of claim 19, wherein tremelimumab is to be administered as a fixed dose of 75 mg or as a dose of 1 mg/kg.

27. The use according to any one of claims 19-26, wherein prophylactic cranial irradiation is to be administered to the patient.